S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
|ClinicalTrials.gov Identifier: NCT00043082|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : October 26, 2015
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if carboplatin is more effective with or without liposomal doxorubicin in treating recurrent ovarian epithelial or primary peritoneal cancer.
PURPOSE: Randomized phase III trial to determine the effectiveness of carboplatin with or without liposomal doxorubicin in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer Peritoneal Cavity Cancer||Drug: carboplatin Drug: pegylated liposomal doxorubicin hydrochloride||Phase 3|
- Compare overall survival of patients with platinum-sensitive recurrent ovarian epithelial or primary peritoneal cancer treated with carboplatin with or without pegylated doxorubicin HCl liposome.
- Compare progression-free survival, confirmed complete response rates, and time to treatment failure in patients treated with these regimens.
- Compare the toxicity of these regimens in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to disease measurability (elevated CA 125 only vs nonmeasurable disease only with or without elevated CA 125 vs measurable disease), number of disease sites (2 or fewer vs 3 or more), and serous tumor histology (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive carboplatin IV over 15 minutes and pegylated doxorubicin HCl liposome IV over 1 hour on day 1.
- Arm II: Patients receive carboplatin IV as in arm I. Treatment in both arms repeats every 4 weeks for a total of 15 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed at 4 weeks, every 6 months for 3 years, and then annually for 7 years.
PROJECTED ACCRUAL: A total of 900 patients will be accrued for this study within 4 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||61 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy|
|Study Start Date :||August 2002|
|Primary Completion Date :||June 2007|
|Study Completion Date :||July 2011|
U.S. FDA Resources
Experimental: carboplatin and doxorubicin
carboplatin and liposomal doxorubicin given q 4 weeks
intravenous q 4 weeksDrug: pegylated liposomal doxorubicin hydrochloride
intravenous q 4 weeks
Active Comparator: carboplatin
intravenous q 4 weeks
- overall survival [ Time Frame: ten years ]From date of registration to date of death
- progression free survival and response [ Time Frame: 10 years ]response by RECIST criteria
- side effects [ Time Frame: 15 months ]side effects described per NCI CTC version 2.0
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00043082
Show 91 Study Locations
|Study Chair:||David S. Alberts, MD||University of Arizona|